Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - MAURIS

NCT04028050 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04028050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04028050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - MAURIS
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
August 12, 2019
Completion date
July 13, 2023
Enrollment
155 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma